Baystreet Staff - Monday, September 28, 2026 Oncolytics Biotech Inc 10:01 AM EST - Oncolytics Biotech Inc : Announced continued clinical and operational progress in REO 033, its randomized study evaluating pelareorep in second-line RAS-mutant, microsatellite-stable (“MSS”) metastatic colorectal cancer. Oncolytics Biotech Inc shares N.ONCY are trading up one cent at $0.70. Full Press Release: https://www.baystreet.ca/quotedata/quote.aspx?ticker=ONCY&qmodStoryID=7707766911644710
